(Q38472303)

English

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

scientific article published on September 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

based on heuristic

inferred from title

author name string

P-L Kellokumpu-Lehtinen

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Hjälm-Eriksson

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C Thellenberg-Karlsson

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

L Åström

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

L Franzen

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

T Marttila

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Seke

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Taalikka

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C Ginman

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

SPCG-13

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

303-307

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

High-risk localized prostate cancer: role of radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

The management of high risk prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Radiation therapy combined with hormone therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for hi

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Health related quality of life for men treated for localized prostate cancer with long-term followup

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

Update on radiation-based therapies for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

The current status of image-guided external beam radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

21 January 2018

International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

31 March 2020

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

31 March 2020

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

31 March 2020

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

31 March 2020

Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

31 March 2020

Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.13

31 March 2020

Identifiers

10.1038/PCAN.2012.13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38472303&oldid=2201744927"